Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized open-label phase 2 study of boosted tipranavir dose regimens in treatment-naive HIV-1 infection
2006-005256-33Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tipranavir and ritonavir in Human immunodeficiency virus infection type 1 (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Steady-state pharmacokinetics, Short-term efficacy and 1 more. Started Jun 2007; status: completed.
02
Drugs
tipranavirritonavir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2006-005256-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005256-33.